Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Pharmaceutical R. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel 1-aza-5-germanocarbobicyclo[3.3.3]undecane synthesis via patent CN112194674B. Stable air-tolerant intermediates for advanced material manufacturing.
Advanced preparation of Maropitant intermediates via transition metal catalysis. High purity, >99% ee, and scalable routes for pharmaceutical manufacturing.
Patent CN101289441A details a cost-effective urea-based synthesis for Carisoprodol. This method offers significant supply chain advantages and reduced manufacturing costs for API producers.
Patent CN102391243A details a novel 7-step synthesis for Atorvastatin intermediates, eliminating expensive lithium reagents and improving supply chain reliability.
Patent CN114437089A reveals a safer, high-yield route for Nalfurafine intermediate NAHY-2 using formic acid transfer hydrogenation, offering significant cost and supply chain advantages.
Patent CN113354599A reveals a safer, high-yield route for Nintedanib key intermediates using hydrazine reduction, offering significant cost reduction in API manufacturing.
Novel metal-free pyrrole synthesis patent offers high yield and reduced contamination for reliable pharmaceutical intermediate supply chains.
Patent CN103588841A details a novel ketalization method for high-purity estriol refining, offering significant cost reduction and supply chain reliability for hormone manufacturing.
Novel synthesis route for avanafil intermediate ensures high purity and safety. Cost-effective production scale-up for pharmaceutical supply chains globally seeking reliable partners.
Novel low-temperature route for erlotinib intermediates eliminates noble metals. Reduces costs and improves supply chain stability for API manufacturing.
Patent CN108101841B details a controlled hydrogenation method for Indacaterol, significantly reducing Impurity A and enhancing manufacturing efficiency for global supply chains.
Patent CN111349014A reveals a safer, high-yield route for Methyl (methylamino)squarate, eliminating hazardous solvents and reducing manufacturing costs for global supply chains.
Novel convergent route for Gefitinib intermediates eliminating chromatography. High yield, scalable process for pharmaceutical manufacturing supply chains.
Patent CN110143973B reveals a novel inorganic salt salification process for Flomoxef Sodium, eliminating organic acid residues and ensuring superior stability for pharmaceutical manufacturing.
Patent CN117263941B reveals a novel EGFR inhibitor synthesis with high purity and atom economy. Discover cost reduction and supply chain advantages for pharmaceutical manufacturing.
Novel patent CN120842228A offers high-yield synthesis for HIV and JAK inhibitor intermediates, ensuring cost reduction and supply chain reliability for global manufacturers.
Patent CN106423281A reveals a novel rare earth silamide catalyst for efficient spiro[cyclopropane-1,3'-indole] synthesis, offering mild conditions and cost reduction.
Novel rare earth silamide catalyzed one-pot synthesis for high-purity spiro[cyclopropane-1,3'-indole] intermediates. Cost-effective and scalable pharma manufacturing.
Patent CN110878064A reveals a breakthrough synthesis route for febuxostat impurities, boosting total yield from 0.2% to 43% via strategic intermediate sequencing.
Novel 5-step synthesis from D-Glutamic acid for DPP-IV inhibitors. High yield, mild conditions, and cost-effective industrial manufacturing process.